The U.S. Patent and Trademark Office (USPTO) today announced a webpage to help small and micro businesses apply for streamlined consideration for products that require FDA approval for COVID-19 use.
The COVID-19 Prioritized Examination Pilot Program, announced May 8, will allow up to 500 qualifying patent applications to be accepted for priority examination and be exempted from priority examination fees. The USPTO will try to reach a final decision on each application within six months if applicants respond promptly its communications, according to the patent office.
Get the full story on our sister site, Medical Design & Outsourcing.
Filed Under: Drug Discovery, Drug Discovery and Development
